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Summary Interferon (IFN) shows no specificity in inhibiting the growth of colonies of myeloid leukaemia
blasts in culture as compared to normal haemopoietic precursors, but does reduce the self-renewal capacity of
myeloblasts. We have tested the ability of IFN to slow the leukocyte doubling time (Ldt) and to prolong
remissions induced by busulphan in 14 patients with chronic granulocytic leukaemia (CGL). Patients served as
their own controls; the Ldt during relapse from a busulphan-induced remission on no therapy was determined
and compared with the Ldt on IFN maintenance therapy. The initial dose of IFN (2 x 106UM-2 sub-
cutaneously, three times per week) was adjusted up, or down, to prevent the leukocyte count from rising and
the platelet count from falling below 75 x i0 1-'. The dose of IFN required to prevent relapse in seven
patients ranged from 1 x 106U M2 three times per week to 5.2 x 106U M2 daily, with a median of
2 x 106 U M-2 three times per week. IFN maintenance therapy has prevented relapse in six patients for more
than 22 months to more than 68 months. In five patients the Ldt was slowed initially but the disease later
progressed in four patients to enter the accelerated (three patients) or blast phase (one patient). The Ldt
during IFN therapy did not change from the Ldt on no therapy in one patient; this patient later progressed to
the blast phase. In two additional patients the leukaemia progressed during the first course of IFN, with
shortening of the Ldt; both of these patients entered the blast phase. In the four patients who have
discontinued IFN following relapse in the chronic phase, the Ldt remained prolonged for at least one relapse
after the IFN was stopped. IFN maintenance therapy failed to control the leukocyte count in the six patients
with a control Ldt of less than 40 days and five of these have progressed to enter the accelerated or blast
phase. The early survival of this group of patients resembles the survival of 'good risk' CGL patients reported
by others. We conclude that IFN maintenance therapy does alter the relapse pattern of a subset of CGL
patients, either slowing the Ldt or preventing relapse.
Chronic granulocytic leukaemia (CGL) is a clonal myelo-
proliferative disease affecting the haemopoietic stem cell. A
translocation of the c-abl proto-oncogene from the end of
chromosome 9 to the break point cluster region (bcr) of
chromosome 22, with the formation of a new gene (abl/bcr),
occurs in virtually all patients, although the translocation can
be recognised morphologically as the Philadelphia
chromosome (Ph') in only 90-95% (Kantarjian et al., 1988).
Patients present with a myeloid leukocytosis, anaemia,
splenomegaly and weight loss. These manifestations are easy
to control initially by treatment with busulphan or hydroxy-
urea. Disease progression becomes evident early in the course
of CGL, and is manifested by an increase in the growth rate
of the leukaemic population, so that the remissions become
shorter and shorter as the leukocyte doubling time decreases
with each successive relapse. After passing through an
accelerated phase, increasing anaemia and thrombocytopenia
develop as the marrow is replaced by myeloid, erythroid,
megakaryocytic or lymphoid blast cells. The blast phase of
the disease may respond to an altered form of treatment, but
the remissions are short and death usually ensues within a
year (Bergsagel, 1983).
None of the treatments devised for CGL (aside from
allogeneic or syngeneic marrow transplantations) has altered
the course of the disease. Survival is determined by the time
required for the disease to progress to the blast phase, and
since none of the chemotherapeutic approaches to the treat-
ment of CGL have succeeded in delaying or preventing the
onset of the blast phase, there has not been an improvement
in survival over that reported by Minot and others for
untreated patients (Kantarjian et al., 1988; Bergsagel, 1967;
Minot et al., 1924).
We became interested in testing the effect of interferon on
the course of CGL as a result of the demonstration that
interferon reduces the self-renewal capacity of myeloblast
colony forming cells (Taetle et al., 1980). Numerous clinical
trials have shown that interferon alone can achieve satisfac-
tory haematological remissions in about 70% of patients,
with recovery of normal marrow metaphases to more than
65% in about one-third of patients (Kantarjian et al., 1988;
Talpaz et al., 1986, 1987; Morra et al., 1987; Niederle et al.,
1987; Ozer, 1988). The Ph' chromosome disappeared from
the marrow metaphases in a number of these patients.
In this study we have followed the leukocyte doubling time
(Ldt) as an index of disease progression. Galton (1959) was
the first to report the progressive shortening of the Ldt
during relapses from busulphan-induced remissions in CGL
patients. Later studies revealed that this progressive increase
in the regrowth rate of the leukemic population was a consis-
tent feature of CGL patients, and that there was a good
correlation between the Ldt and survival (Bergsagel, 1967).
Thus, the Ldt is a strong prognostic factor in CGL, with the
longer doubling-times being associated with better survival.
Materials and methods
To be eligible for this study patients had to be in the chronic
phase of chronic granulocytic leukaemia (CGL). The
presence of the Ph' chromosome, or bcr rearrangement, was
not required for the diagnosis of CGL when this study was
started. Patients with more than 10% myeloblasts in the
blood or marrow differential, persistent platelet counts of less
than 100 x 109 1', and those in whom the leukaemia could
not be controlled with busulphan alone, were not entered.
Patients were required to sign informed consent forms before
entry on study.
The study design is illustrated in Figure 1. Patients were
treated with busulphan, 4-6 mg per day, to bring the
leukocyte count below 10 x 1091-'. Busulphan was then
stopped, and the leukocyte doubling time (Ldt) during the
relapse on no therapy was determined by plotting the total
leukocyte count on a logarithmic scale versus time in days on
a linear scale. Busulphan was restarted when the leukocytes
rose above 30 x 109[1', and continued until the count again
fell below 10 x 109'1-. Recombinant interferon x-2b (IFN,
Intron A, provided by Schering Canada, Inc.) was then
started in a dose of 2.0 x 106 units m-2 of body surface area,
subcutaneously, three times per week. The dose of IFN was
increased, or decreased, until a dose that prevented a rise in
leukocytes above 10 x 1091-l, and did not cause a fall in
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Figure 1 Study design for testing the effect of Interferon (IFN)
on the leukocyte doubling time (Ldt) during relapse from a
busulphan-induced remission. Patients are allowed to relapse on
no therapy after treatment with 4-6 mg busulphan per day to
determine the control Ldt. When the leukocyte count rises above
30 x 1O1-', busulphan is restarted. When the count falls below
10 x I09I l busulphan is stopped and IFN is started. If IFN has
no effect the Ldt will shorten, as shown in curve 1; or the Ldt
may be slowed (curve 2), or relapse may be prevented (curve 3).
leukocytes below 2 x 1091`, or a fall in platelets below
75 x 109 1`, was established. This dose was then continued
until the leukocyte count rose above 30 x 1091-1. If the
leukocyte count could not be controlled with IFN
maintenance therapy, the Ldt was determined. In patients
treated with bulsulphan alone, the Ldt becomes progressively
shorter with successive relapses. Three possible results are
illustrated in Figure 1. In the relapse labelled 1, the IFN fails
to influence the course of the disease, and the Ldt becomes
shorter than the control Ldt on no therapy. In the relapse
marked 2, the Ldt is slowed, and in 3 a rise in leukocytes
above 10 x 109 -' is prevented by IFN maintenance therapy.
Thus, each patient acts as their own control, for we com-
pared the Ldt on IFN maintenance therapy with their
original Ldt on no therapy. IFN was stopped when the
disease progressed to enter the accelerated or blast phase.
Karyotypes of marrow cells were done before and after
starting IFN. G-banded chromosome studies were done on
direct marrow preparations, and on marrow cells cultured for
24 h in the absence of phytohaemagglutin, by Dr Ian Dube
and his associates in the University of Toronto Hospitals
Cancer Cytogenetics Laboratory.
Studies of the structure of the leukocyte DNA of cases 4, 5
and 11, using three restriction enzymes (Bam H1, Eco RI
and Hind iii) and Southern blot analysis with cDNA probes
for the major bcr region (Canaani et al., 1984), were done by
our colleague Dr Mark Minden.
Results
The characteristics of the 14 CGL patients entered in this
study are shown in Table I. All these patients were still in the
chronic phase of the disease and responsive to busulphan. All
had received prior treatment with busulphan because the
study design required the determination of the Ldt during a
relapse on no therapy from a busulphan-induced remission.
The interval from diagnosis to starting IFN ranged from 3 to
60 months, with a median of 14.5 months. The median age
was 45 years, with a range of 23-67. There were four females
and 10 males.
A typical Ph' chromosome was detected in the
chromosome analysis of all patients, except for cases 4 and
5, who had an extra 21 chromosome, and case 11, who had a
normal karyotype. Marrow cells or DNA for case 4 were not
available for study. The studies of the marrow cell DNA of
cases 5 and 11 have shown bcr rearrangement.
The influence of IFN maintenance therapy is illustrated in
Figure 2. There has not been a rise in leukocyte count above
30 x 1091-' in six patients (cases 2, 3, 7, 11, 12 and 13). An
additional patient case (case 9) had a stable leukocyte count
below 10 x 109 1-1 for 8 months, which then began to rise,
Table I Clinical features of chronic phase chronic granulocytic
leukaemia patients treated with r interferon a-2b
Monthsfrom
Case Age/sex Karyotype Prior treatment DX to IFN
1 42/M 46,XY,t(9:22) Busulphan 24
2 23/M 46,XY,t(9:22) Busulphan 33
3 34/F 46,XX,t(9:22) Busulphan 25
4 67/M 47,XY, + 21 Busulphan 5
5 54/M 47,XY, + 21 Busulphan 9
6 43/M 46,XY,t(9:22) Busulphan 3
7 51/M 46,XY,t(9:22) Busulphan 15
8 58/F 46,XX,t(9:22) Hydroxyurea, 60
Busulphan
9 43/F 46,XX,t(9:22) Busulphan 34
10 36/M 46,XY,t(9:22) Busulphan 12
11 41/M 46,XY Hydroxyurea, 24
Busulphan
12 42/M 46,XY,t(9:22) Busulphan 14
13 46/M 46,XY,t(9:22) Busulphan 8
14 46/F 46,XX,t(9:22) Hydroxyurea, 6
Busulphan
despite continued IFN therapy, with an Ldt of 38 days. The
Ldt was slowed in five patients (cases 1, 4, 8, 9 and 14)
during the first course of IFN maintenance therapy. The Ldt
on the first course of IFN was identical with the control Ldt
in one patient (case 5). The Ldt shortened during the first
course of IFN in two patients; in case 6 from 70 days on no
maintenance to 17 days on IFN, and from 20 to 11 days in
case 10. Both these patients progressed to enter the blast
phase during their first course of IFN. The Ldt on subse-
quent courses of IFN are shown as open circles in Figure 2.
Cases 1, 4 and 5 had progressive shortening of the Ldt until
the Ldt on IFN became shorter than the control Ldt on no
therapy. The Ldt during additional courses of IFN could not
be determined for case 8 (refused further IFN) or case 9
(placed on IFN plus hydroxyurea). The Ldt on IFN in case
14 has not shortened appreciably as yet. Of the eight patients
in whom the leukocyte count could not be controlled by
maintenance IFN therapy, seven have progressed to enter the
accelerated (cases 1,4 and 9) or blast (cases 5, 6, 8 and 10)
phases of the disease, and only one remains in the chronic
phase (case 14).
It will be noted that none of the six CGL patients with a
control Ldt of less than 40 days could be controlled by IFN
maintenance therapy, and all but one have progressed to the
accelerated or blast phase. Of the eight CGL patients with
control Ldt of 48 days or more, only two (cases 5 and 6)
could not be controlled for prolonged periods with
maintenance IFN.
> 120 co
0 100
. a> 80
:a)
° ' 60
)D0
0 ° 40 0 0
= 20
0 0
0
Cases with leukocytes
maintained
<30 x 109 L-1 (months)
> 11 (28+)
> 2 (43+)
12 (28+)
13 (22+)
3 (68+)
7 (38+)
20 40 60 80 100 120
Leukocyte doubling-time (days)
on interferon
Figure 2 Influence of IFN maintenance therapy on the leukocyte
doubling-time (Ldt) of CGL patients. The control Ldt on no
therapy and the Ldt during the first course of IFN are plotted as
solid circles; a case number, from Table I, is shown for each
point. The Ldt during subsequent relapses on IFN are shown as
open circles. The control Ldt for the six patients who have not
shown a rise in leukocyte count above 30 x 1091' while receiving
IFN, are shown on the right side of the figure, together with the
number of months since IFN was started.
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The dose of IFN required to maintain the leukocyte count
below 10 x I09 1' is shown in Table II for the six patients
who have not relapsed (cases 2, 3, 7, 11, 12 and 13), and an
additional patient who was controlled for 8 months and then
relapsed (case 9). The required dose of IFN ranged from
1 x 106 UM-2 three times per week to 5.2 x 106 U M-2 daily,
with a median of 2 x 106 UM-2 three times per week.
The delaying effect of IFN therapy on the regrowth rate of
the leukaemic population (the Ldt) persisted after IFN
therapy was discontinued. This is shown in Table III for all
of the patients who have had their Ldt determined before,
during and after stopping IFN. It will be noted that the first
Ldt after stopping IFN did not become shorter than the
preceding Ldt determined while on IFN in any of these
patients. In case 14, however, the Ldt during the second
relapse after stopping IFN, did shorten to 10 days, a value
similar to the Ldt before IFN. Subsequent maintenance IFN
therapy has again slowed the relapse LDT in case 14. In this
case IFN therapy has delayed progression by at least 21
months.
Cases 5 and 6 have died in blast crisis. Case 4 showed
progression of the leukaemia, with shortening of the Ldt, but
died from the complications of severe chronic obstructive
pulmonary disease, rather than leukaemia.
Marrow transplantation from HLA compatible siblings
has been attempted for two patients. The experience with the
marrow transplant for case 1 was instructive. This man
responded with lengthening of the Ldt to 112 days (com-
pared to a control Ldt of 31 days on no therapy) during the
first course of IFN. IFN was started again after a course of
busulphan, but the disease could not be controlled and the
Ldt shortened to 23 days. A marrow karyotype revealed the
development of an additional Ph' chromosome, and other
chromosome abnormalities (46, XY, - 13, + 22, t(9:22)
(q34; qll), 9q-). When busulphan failed to control the
relapse the patient was prepared for a marrow transplant
with cytosine arabinoside 60 mg intravenously every 8 h for 5
days (15 doses), followed by cyclophosphamide 3,840 mg
intravenously on days 6 and 7. Plasmaphoresis was done on
days 8, 9 and 10. After total body irradiation of 500 cGy in
one fraction on day 11, a transplant of 2.3 x 1010 nucleated
marrow cells from a tissue-compatible sister was
administered. Cyclosporin A, in a dose of 6.25 mg kg-' by
month every 12 h, was started 1 day before the marrow
transplant and continued for 6 months. Marrow recovery
was prompt with a rise in platelets to 129 x I0'1-' by day
Table II Dose ofr interferon x-2b required to maintain the leukocyte
count under 10 x 109 1-1
Case Dose M2 (total) and schedule
2 2 x 106 (3.5) 3 x week
3 2 x106 (3.1) 3 x week
7 1.5 x 106 (3.0) 3 x week
9 2 x 106 (3.8) daily
11 I X 106 (2.0) 3 x week
12 2 x106 (4.0) 3 x week
13 5.2 x 106 (10.0) daily
23, and neutrophils rose above 1 x 109 by day 45. Marrow
chromosome studies on day 223 revealed 2 of 48 metaphases
with a normal female karyotype (46, XX), and 46 metaphases
representing male cells with the Ph' chromosome and other
abnormalities (46, XY, t(9:22) (q34; ql1) 9q-, lOp +,
13q-). These findings indicated that most of the dividing
cells in the marrow were derived from the recipient's
leukaemic population, but that a small proportion were
derived from the female donor's marrow. At this time the
patient's leukocyte count was rising, and the spleen was
enlarged. He was started on rIFN-m2b in a dose of 3.5 x 106
units subcutaneously three times a week. After 76 days of
IFN therapy the leukocyte count had fallen to 2.7 x 101l',
and the dose of IFN was reduced to 2.5 x 106 units three
times a week. The patient was pancytopenic (haemoglobin
79 g 1', leukocytes 0.6 x 10 1'-, 100% lymphocytes,
platelets 15 x 109 -l') after 88 days of IFN, and this therapy
was stopped. He received supportive care with antibiotics,
and transfusions of erythrocytes and platelets. There has
been a slow recovery of neutrophils, and a gradual reduction
in the requirement for red cell and platelet transfusions, but
the patient remains thrombocytopenic. A marrow aspiration
obtained 9 months after stopping IFN produced 12 normal
female 46, XX karyotypes, and 2 months later eight normal
female metaphases were obtained from the marrow. The
most recent chromosome studies, done on a marrow sample
obtained 15 months after stopping IFN, had 11 normal
female (46, XX) metaphases, and five female cells with
monosomy 7 (45, XX, -7).
These observations suggest that the preparative
chemotherapy and total body irradiation used for this mar-
row transplant did not eliminate the Ph'-positive leukaemic
population. Male Ph'-positive cells repopulated the marrow
and accounted for 46 of 48 marrow metaphases examined
223 days after the marrow transplant. IFN treatment
eliminated the Ph'-positive cells but rendered the patient
pancytopenic. Since this treatment was stopped there has
been a slow repopulation of the marrow with donor female
cells. The recent discovery of a population of female cells
with monosomy 7 raises the fear of a malignant change in
these cells.
The Ph'-positive leukemic population also regenerated in
the second patient (case 10) receiving a marrow transplant.
In this patient, however, IFN therapy failed to eliminate the
leukaemic population, and he has died with sepsis comp-
licating the blast phase and its treatment.
Only two of the 11 patients with a recognisable Ph'
chromosome have had a return of normal metaphases to
their marrow chromosome spreads. The population of Ph'-
positive metaphases has dropped from 100% to four of 22
(18%) after 24 months on interferon (case 7), and to 21 of 25
(84%) after 12 months for case 12. Case 7 continues on
2.0 x 106 units M-2 three times a week, while the dose has
been reduced to 1.5 x 106 units M-2 three times a week for
case 12.
The survival of this cohort of patients is shown in Figure
3, together with the survival of 813 Ph'-positive 'good risk'
CGL patients in the chronic phase, treated with conventional
Table III Effect of r interferon a-2b on leukocyte doubling time
Leukocyte doubling time (days)
Control (before During interferon Subsequent relapses
Patient interferon) (dose) (after stopping interferon)
4 30 (4.6MU 3 x wk) 45 50
(9.2MU 3 x wk) 46
5 92 (4.OMU 3 x wk) 92 112
7 19 (3.7MU 3 x wk) 26 58
44
14 8 (3.5MU 3 x wk to 41
daily) 42 10
(7MU day-') 41
(IOMU day-') 51898 D.E. BERGSAGEL & H. MESSNER
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Figure 3 Survival of 14 patients with chronic granulocytic
leukaemia (CGL) treated with maintenance IFN and a reference
survival curve for the survival of 'good-risk' CGL patients
treated with conventional chemotherapy. In the IFN group there
have been three deaths; in addition, two patients receiving
allogeneic marrow transplants were counted as dead at the time
of transplantation.
chemotherapy (mostly busulphan and hydroxyurea) reported
by Sokol et al. (1984). Although one of the two patients who
received marrow transplants is still alive, both were counted
as dead on the day of the transplant for this survival curve.
The early survival for the IFN maintained patients has been
very similar to that of patients treated with conventional
chemotherapy.
Discussion
IFN clearly altered the course of CGL in some of these
patients, slowing the Ldt during relapse in five patients and
preventing relapse for from more than 22 months to more
than 68 months in six patients. The dose of IFN required to
control the leukocyte count has ranged from 1 x 106 units
M-2 subcutaneously three times a week to 5.2 x 106 units M-2
daily. The persistence of the slowed Ldt long after IFN
therapy was stopped indicates that this treatment did induce
a persistent change in the growth of the leukaemic popula-
tion.
The leukocyte count could not be controlled by IFN
maintenance therapy in any of the patients with a control
Ldt of less than 40 days. This observation suggests that IFN
is most effective when it is administered early in the course of
CGL, and that it is relatively ineffective once the disease has
progressed to the stage that the Ldt has shortened to less
than 40 days. Still, IFN did not alter the course of the
disease in all patients, for at least 4 have progressed to enter
the blast phase of the disease.
The return of normal metaphases to the marrow of a
substantial proportion of CGL patients after treatment with
IFN has been encouraging (Talpaz et al., 1986, 1987; Morra
et al., 1987; Niederle et al., 1987; Ozer, 1988). The observa-
tion that normal metaphases reappeared in the marrow of 2
of our patients, and that IFN treatment resulted in the
disappearance of Ph'-positive cells following marrow trans-
plantation in another adds further support to the view that
IFN either selectively inhibits the growth ofPh'-positive cells,
or frees normal haemopoietic precursor cells from suppres-
sion by a factor produced by the leukaemic cells.
The observations that IFN maintenance therapy has
prevented relapse in six patients, has slowed the Ldt in an
additional five patients and reduced the proportion of Ph'
chromosome positive metaphases, are encouraging. However,
IFN therapy has failed to prevent progression of CGL to the
blast phase in four patients, and three have entered the
accelerated phase. It is too early to judge whether IFN
maintenance therapy will delay the onset of the blast phase in
some patients, and prolong survival. The design of our study
does not allow us to draw any conclusions regarding the
influence of IFN maintenance therapy on survival. IFN may
have a beneficial effect on only a subset of patients, and the
determination of the value of this form of treatment will
require large randomised studies, such as the MRC trial of
IFN in chronic myeloid leukaemia, and another in the
Federal Republic of Germany (Hehlmann et al., 1989).
This study was supported by a grant and supplies of r interferon
a-2b (Intron A) from Schering Canada Inc. Preliminary reports of
the design of this study have been published.
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